Primary tumors of the heart are rarely seen. Cardiac angiosarcomas are malignant tumors that almost always have a poor prognosis. We describe a 29-year-old man with primary cardiac angiosarcoma with multiple site metastases. The therapeutic approach includes surgery, chemotherapy and radiotherapy alone or in combination. New techniques of radiotherapy and combined chemotherapeutic agents may relieve symptoms and prolong a patient's life. We discuss the diagnosis and treatment of cardiac angiosarcoma in the light of a case report.
ChidelM.A., MacklisR.M.: Tumors of the heart and great vessels. In: Principles and practice of radiation oncology,PerezC., BradyL.W., HalperinE.C., Schmidit-UllrichR.K. (Eds), pp 1305–1314, Lippincott Williams and Wilkins, Philadelphia, 2004.
2.
OrmerodO.J.M., SprattP.M., LewisN.P., WallworkJ.: Primary angiosarcoma of the heart mimicking a left atrial myxoma.Thorax, 39: 798–799, 1984.
3.
BurkeA.P., CowanD., VirmaniR.: Primary sarcomas of the heart.Cancer, 69: 387–395, 1992.
4.
DeetjenA.G., ConradiG., MöllmannS., HammC.W., DillT.: Cardiac angiosarcoma diagnosed and characterized by cardiac magnetic resonance imaging.Cardiol Rev, 14: 101–103, 2006.
CentofantiP., Di RosaE., DeorsolaL., DatoG.M., PataneF., La TorreM., BarbatoL., VerziniA., FortunatoG., Di SummaM.: Primary cardiac neoplasms: early and late results of surgical treatment in 91 patients.Ann Thorac Surg, 68: 1236–1241, 1999.
8.
GrebencM.L., Rosado de ChristensonM.L., BurkeA.P.: Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation.Radiographics, 20: 1073–1103, 2000.
9.
FortmannT.: Hemorrhagic nonspecific pericardial effusion as an initial symptom of angiosarcoma of the right heart.Z Kardiol, 93: 807–812, 2004.
10.
LofflerH., GrilleW.: Classification of malignant cardiac tumors with respect to oncological treatment.Thorac Cardiovasc Surg, 38: 173–175, 1990.
11.
EngelenM., BruchC., HoffmeierA., KerstingC., StypmannJ.: Primary left atrial angiosarcoma mimicking severe mitral valve stenosis.Heart, 91: 27–30, 2005.
MengQ., LaiH., LimaJ., TongW., QianY., LaiS.: Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 patients.Int J Cardiol, 84: 69–75, 2002.
14.
InokoM., IgaK., KyoK., KondoH., TamuraT., IzumiC., KitagichiS., HirozaneT., HimuraY., GenH., KonishiT.: Primary cardiac angiosarcoma detected by magnetic resonance imaging but not by computed tomography.Intern Med, 40: 391–395, 2001.
15.
HoffmeierA., ScheldH.H., TjanT.D., SchneiderM., KerberS., SchmidtT., SchmidC.: Ex situ resection of primary cardiac tumors.Thorac Cardiovasc Surg, 51: 99–101, 2003.
16.
SilvestrisN., PiscitelliD., CrucittaE., FioreM., De LenaM., LorussoV.: Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report.J Chemother, 15: 507–509, 2003.
17.
PatelS.R., GandhiV., JenkinsJ., PapadopolousN., BurgessM.A., PlagerC., PunkettW., BenjaminR.S.: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.J Clin Oncol, 19: 3483–3489, 2001.
18.
LookK.Y., SandlerA., BlessingJ.A., LucciJ.A.III, RoseP.G.: Phase II of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study.Gynecol Oncol, 92: 644–647, 2004.
19.
HartmannJ.T., OechsleK., HuoberJ., JakobA., AzemarM., HorgerM., KanzL., BokemeyerC.: An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.Invest New Drugs, 24; 249–253, 2006.
20.
OkunoS., RyanL.M., EdmonsonJ.H., PriebatD.A., BlumR.H.: Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of Eastern Cooperative Oncology Group.Cancer, 97: 1969–1973, 2003.
21.
Spath-SchwalbeE., GenvresseI., KoschuthA., DietzmannA., GrunewaldR., PossingerK.: Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.Anticancer Drugs, 11: 325–329, 2000.
22.
SvancarovaL., BlayJ.Y., JudsonI.R., van HoselQ.G., van OosteromA.T., le CesneA., KeizerH.J., HermansC., van GlabbekeM., VerweijJ., HogendoornP.C., NielsenO.S.: Gemcitabine in advanced adult soft-tissue sacomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.Eur J Cancer, 38: 556–559, 2002.
23.
van HoeselQ.G., VerweijJ., CatimelG., ClavelM., KerbratP., van OosteromA.T., KergerJ., TurszT., van GlabbekeM., van PottelsbergheC.: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcoma of the adult. EORTC Soft Tissue and Bone Sarcoma Group.Ann Oncol, 5: 539–542, 1994.
24.
SpiridonidisC.H., LaufmanL.R., JonesJ., RhodesV.A., WallaceK., NicolS.. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.J Clin Oncol, 16: 3866–3873, 1998.
25.
GeorgouliasV., KouroussisC., AndroulakisN., KakolyrisS., DimopoulosM.A., PapadakisE., BourosD., ApostolopoulouF., PapadimitriouC., AqelidouK., HatzakisK., KalbakisK., KotsakisA., VardakisN., VlachonicolistJ.: Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.J Clin Oncol, 17: 914–920, 1999.
26.
HensleyM.L., MakiR., VenkatramanE., GellerG., LovegrenM., AghajanianC., SabbatiniP., TongW., BarakatR., SpriggsD.R.: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.J Clin Oncol, 20: 2824–2831, 2002.
27.
LeuK.M., OstruszkaL.J., ShewachD., ZalupskiM., SondakV., BiermannJ.S., LeeJ.S.J., CouwlierC., PalazzoloK., BakerL.H.: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.J Clin Oncol, 22: 1706–1712, 2004.
